VANCOUVER, BRITISH COLUMBIA – Helix BioPharma Corp. (TSX: HBP, OTC PINK: HBPCD, FRANKFURT: HBP0), a clinical-stage oncology company, announced changes to its Board of Directors effective immediately. Janusz Grabski has resigned from the board, and Thomas Mehrling, M.D., Ph.D., the company’s Chief Executive Officer, has been appointed as a director. The appointment was made pursuant to a board nomination right granted to Laevoroc Immunology AG in connection with Helix’s 2025 acquisition of substantially all of the assets of Laevoroc Immunology AG and Laevoroc Chemotherapy AG.
The company stated that these changes are intended to ensure that the board continues to meet Helix’s evolving governance and capital markets requirements and has the composition and experience needed to support the company’s clinical development and broader corporate objectives. The board expressed gratitude to Mr. Grabski for his service and contributions.
This leadership adjustment comes at a pivotal time for Helix, which is advancing a pipeline focused on difficult-to-treat cancers. The company’s lead candidate, L-DOS47, is an antibody-enzyme conjugate in clinical development as a combination therapy for non-small cell lung cancer (NSCLC). Additionally, Helix is developing LEUMUNA™, a pre-IND oral immune checkpoint modulator for post-transplant leukemia relapse, and GEMCEDA™, a pre-IND gemcitabine prodrug for advanced solid tumors. These candidates were part of the strategic acquisition from the Laevoroc Group, which Helix detailed in a press release on its website.
The board changes are seen as a move to streamline governance and align leadership with the company’s strategic direction. By bringing the CEO onto the board, Helix aims to strengthen the alignment between management and board oversight, which may be crucial as the company progresses its clinical programs and seeks to meet capital market expectations.
Helix BioPharma is listed on the Toronto Stock Exchange (TSX: HBP), quoted on the OTC Pink Market (HBPCD), and listed on the Frankfurt Stock Exchange (FWB: HBP0). The company is focused on developing therapies for underserved patient populations with difficult-to-treat cancers, a mission that underscores the importance of its current pipeline and corporate decisions.
For more information about Helix BioPharma and its pipeline, visit the company’s website. The appointment of Dr. Mehrling, who has served as CEO, brings a deeper integration of leadership, potentially enhancing decision-making processes as the company navigates the complexities of oncology drug development.
